<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1996">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635504</url>
  </required_header>
  <id_info>
    <org_study_id>H12-00990</org_study_id>
    <nct_id>NCT01635504</nct_id>
  </id_info>
  <brief_title>HIV Posterior Cheek Enlargement</brief_title>
  <official_title>Posterior Cheek Enlargement in HIV: Anatomic Characterization and Treatment With Botulinum Toxin A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Altered contour of the lower face is a frequent complication of human immunodeficiency virus
      (HIV). HIV facial lipoatrophy or loss of facial fat commonly results from antiretroviral
      therapy. Posterior cheek enlargement leading to a bulky and widened lower facial contour can
      also be seen in HIV. These changes can lead to significant cosmetic disfigurement and have
      an enormous psychosocial impact on patients. They also make individuals vulnerable by making
      them recognizable as persons living with HIV. Posterior cheek enlargement has not been well
      characterized. Both the parotid salivary gland and the masseter muscle are located in the
      posterior cheek region. Although parotid gland enlargement in a common complication of HIV,
      it is unknown whether enlargement of the masseter muscle also contributes. The investigators
      plan to study posterior cheek enlargement in HIV positive individuals. The investigators
      also plan to use botulinum toxin A as a novel treatment to improve the altered lower facial
      contour seen in HIV. This treatment has already demonstrated efficacy in HIV negative
      individuals with enlargement of the masseter muscle. Botulinum toxin has also been used
      safely in the salivary glands in individuals with excessive drooling resulting from
      neurological disease. In a trial HIV+ patient, the investigators have already demonstrated
      the efficacy of using botulinum toxin A in the treatment of posterior cheek enlargement,
      resulting from both parotid and masseter muscle enlargement. The investigators anticipate
      this study will increase our understanding of posterior cheek enlargement in HIV and lead to
      the development of a novel treatment for this important complication.

      The investigators hypothesize that posterior cheek enlargement in HIV+ patients will in some
      cases result from both masseter muscle hypertrophy as well as parotid gland enlargement. The
      investigators also hypothesize that the treatment of posterior cheek enlargement with
      botulinum toxin A will result in a more aesthetically appealing lower facial contour in HIV+
      patients. This has already been demonstrated in a trial HIV+ patient, in which there was a
      dramatic change in the volume of the masseter muscle and parotid gland 12 weeks after
      treatment with botulinum toxin A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND AND SIGNIFICANCE

      Altered contour of the lower face is a frequent complication of HIV and can lead to
      significant cosmetic disfigurement and social stigmatization. However, posterior cheek
      enlargement in HIV is poorly characterized. The parotid and masseter overlie the mandibular
      ramus, thus both contributing to the lower facial contour. Parotid hypertrophy is a
      recognized and common complication of HIV. It is presently unknown whether masseter muscle
      hypertrophy also contributes to this cosmetic deformity. The investigators will conduct a
      prospective pilot study in HIV+ patients to determine whether masseter muscle hypertrophy
      and parotid gland enlargement contribute to a bulky and widened lower facial contour, or
      whether the aesthetic appearance is due primarily to apparent muscle enlargement
      attributable to facial lipoatrophy.

      Development of novel treatments to address these HIV-associated cosmetic changes is
      increasingly important as the burden of this disease expands globally. There have been
      limited advances in salivary gland surgery in recent years. The benign nature of parotid
      gland hypertrophy requires the surgeon to preserve key anatomical structures as an important
      marker of outcome. As such, parotidectomy is a controversial procedure. Treatments for
      masseter hypertrophy include surgical reduction of the masseter muscle and resection of the
      mandibular angle to create a narrower facial width. These surgical treatments can involve
      significant complications such as facial nerve injury, infection, scarring, bleeding,
      swelling and trismus. This highlights the need to develop more treatments for posterior
      cheek enlargement. Botulinum toxin is a highly efficacious and cost-effective, nonsurgical
      option for reducing the width and improving the shape of the lower face and jawline.
      Botulinum toxin for masseter hypertrophy and parotid enlargement in HIV negative individuals
      and sialorrhea in neurological disease is a safe and effective treatment for these
      conditions. However, there are no studies published to date on the use of botulinum toxin in
      the setting of HIV. Furthermore, the investigators have already demonstrated the efficacy of
      using botulinum toxin A in the treatment of posterior cheek enlargement in a trial HIV+
      patient with both parotid enlargement and masseter hypertrophy. This patient had a dramatic
      response clinically and demonstrated a 19.0% and 19.4% mean reduction in the volume of the
      parotid gland and masseter muscle, respectively, 12 weeks after injection of botulinum toxin
      A. He experienced no adverse effects from the injections.

      The investigators will use clinical, photographic and radiological evaluations to determine
      the efficacy and durability of botulinum toxin A for altered lower facial contour in HIV+
      patients. The investigators anticipate that, at a minimum, this study will improve our
      understanding of posterior cheek enlargement seen in some HIV+ patients. The results of this
      study may translate into a novel and evidence-based use of botulinum toxin for management of
      altered lower facial contour in HIV+ patients. This could potentially improve the
      psychosocial wellbeing in patients afflicted with this devastating disease.

      STUDY PROTOCOL

      This will be an initial pilot study with 5 participants. Participants with posterior cheek
      enlargement will have photographs taken and a baseline CT scan of the head performed.
      Botulinum toxin A will be injected by identifying the inferior border of the zygomatic arch
      and mandibular ramus as well as the anterior and posterior demarcation of the posterior
      cheek enlargement. Injections will be performed percutaneously by palpation. A total of 10 U
      will be injected into 5 evenly spaced points of the posterior cheek enlargement to give a
      total dose of 50 U per side.

      Participants will be evaluated clinically at 4, 8 and 12 weeks after injection, with
      photographs, and by a questionnaire assessing patient satisfaction and side effects. A CT
      scan of the head will be performed 12 weeks after injection of botulinum toxin A. Long-term
      efficacy of botulinum toxin A will then be evaluated at 6 and 12 months post injection
      clinically, with photographs and a questionnaire assessing patient satisfaction and side
      effects.

      The primary outcome will be the change in volume of the masseter muscle and parotid gland 12
      weeks after treatment with botulinum toxin A. The mean change and standard deviation will be
      determined. A secondary outcome will be the relative contributions of masseter hypertrophy
      and parotid enlargement to posterior cheek enlargement in HIV+ patients. The pre-treatment
      volume of the masseter muscle and parotid gland determined in our HIV+ participants will be
      compared to those of normal controls published in the literature.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Volume of the Parotid Gland From Baseline to 12 Weeks After Treatment With Botulinum Toxin A</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>HIV Posterior Cheek Enlargement</condition>
  <arm_group>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <description>Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)</description>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 19 and older

          2. Are HIV positive

          3. Have facial lipoatrophy and a clinically widened lower facial contour

        Exclusion Criteria:

          1. Have had previous facial injection of any other products

          2. Have an active infection on the face

          3. Are receiving active treatment with interferon or systemic corticosteroids

          4. Are pregnant or breast-feeding

          5. Have known preexisting renal disease

          6. Have poorly controlled diabetes mellitus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alastair Carruthers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carruthers Dermatology Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 20, 2015</lastchanged_date>
  <firstreceived_date>June 4, 2012</firstreceived_date>
  <firstreceived_results_date>May 27, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV lipoatrophy</keyword>
  <keyword>masseter hypertrophy</keyword>
  <keyword>parotid enlargement</keyword>
  <keyword>botulinum toxin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin A</title>
          <description>Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV Posterior Cheek Enlargement Group</title>
          <description>Patients with HIV posterior cheek enlargement treated with botulinum toxin A</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>parotid gland volumes</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>HIV Posterior Cheek Enlargement Group</title>
            <description>Patients with HIV posterior cheek enlargement treated with botulinum toxin A</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A</title>
            <units>percentage reduction in masseter volume</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21.4" lower_limit="10" upper_limit="27.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Volume of the Parotid Gland From Baseline to 12 Weeks After Treatment With Botulinum Toxin A</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>HIV Posterior Cheek Enlargement Group</title>
            <description>Patients with HIV posterior cheek enlargement treated with botulinum toxin A</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage Change in Volume of the Parotid Gland From Baseline to 12 Weeks After Treatment With Botulinum Toxin A</title>
            <units>percentage reduction in parotid volume</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.2" lower_limit="6.4" upper_limit="14.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HIV Posterior Cheek Enlargement Group</title>
          <description>Injected with botulinum toxin A</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>decrease in bite force</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>change in facial expression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>sunken cheeks</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pilot study with only 5 participants. This study can only serve as a guide for larger studies.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Shannon Humphrey</name_or_title>
      <organization>University of British Columbia</organization>
      <phone>(604) 714-0222</phone>
      <email>shannon@carruthers-humphrey.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
